BIVI实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States...

Stats
今日成交量	312 670
平均成交量	2.59M
市值	26.63M
EPS	$0 ( 2024-02-09 )
下一个收益日期	( $-0.330 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.410
ATR14	$0.00300 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-04	Do Cuong V	Buy	10 000	Common stock
2024-03-04	Do Cuong V	Buy	5 000	Warrants (right to buy)
2023-12-11	Kim Joanne Wendy	Buy	5 000	Common Stock
2023-11-09	Lang James Paul	Buy	93 500	Stock Option (right to buy)
2023-11-09	Gorlin Steve	Buy	46 358	Common Stock

INSIDER POWER
91.56
Last 94 transactions
Buy: 39 235 676 \| Sell: 4 917 434

音量相关性

長: -0.03 (neutral)

短: -0.22 (neutral)

Signal:(48.226) Neutral

Biovie Inc 相关性

10 最正相关
IONM	0.843
CIDM	0.823
AACG	0.818
GAINL	0.807
CERC	0.806
AMRB	0.802

10 最负相关
DBX	-0.895
RMRM	-0.894
PCT	-0.882
PTC	-0.866
NOVT	-0.864
OPEN	-0.861
CVAC	-0.846
XP	-0.845
FTHM	-0.842
EXPI	-0.842

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Biovie Inc 相关性 - 货币/商品

0.22
( neutral )

0.00
( neutral )

-0.21
( neutral )

Biovie Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2023
营收:	$0
毛利润:	$-266 842 (0.00 %)
EPS:	$-1.550

FY	2022
营收:	$0
毛利润:	$-237 421 (0.00 %)
EPS:	$-0.920

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-10.50

Financial Reports:

No articles found.

Biovie Inc

BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease and Phase I clinical trial for the treatment of Parkinson's disease. The company is also developing NE3107, which is in pre-clinical stage for the treatment of multiple myeloma and prostate cancer. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is based in Carson City, Nevada.